OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Kevin Hakimi on the Rationale of the PADRES Trial in RCC

May 24th 2022

Kevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.

Dr. Galsky on the Rationale of the CheckMate 274 Trial in Urothelial Carcinoma

May 24th 2022

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial cancer.

Dr. Shaukat on the Methods Utilized in the PREEMPT-CRC Trial in CRC

May 24th 2022

Aasma Shaukat, MD, MPH, discusses the methods utilized in the PREEMPT CRC trial in colorectal cancer.

Dr. O’Donnell on the Ideal Patients for CAR T-Cell Therapies

May 23rd 2022

Betsy O'Donnell, MD, discusses the ideal patients for CAR T-cell therapies in multiple myeloma.

Dr. Lee on the Importance of Collaboration in Precision Medicine

May 23rd 2022

Kelvin P. Lee, MD, discusses the importance of collaboration in precision medicine.

Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC

May 23rd 2022

Lawrence E. Feldman, MD, discusses the phase 3 LEAP-006 trial evaluating lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Dr. Ailawadhi on the Examination of Iopofosine I-131 in Waldenström Macroglobulinemia

May 20th 2022

Sikander Ailawadhi, MD, discusses the examination of iopofosine I-131 (CLR 131) in Waldenström macroglobulinemia.

Dr. Robesti on Optimizing Patient Selection for Salvage Lymph Node Dissection in Prostate Cancer

May 20th 2022

Daniele Robesti, MD, discusses how to optimize patient selection for salvage lymph node dissection in prostate cancer.

Dr. Lenz on the European Approval of Liso-cel in Relapsed/Refractory LBCL

May 20th 2022

Georg Lenz, MD, discussed the European approval of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

Dr. Deol on Collaboration in the Administration of CAR T-cell Therapy

May 20th 2022

Abhinav Deol, MD, discusses the importance of communication and collaboration in CAR T-cell therapy.

Dr. Vail Discusses Emerging Advances in Biomarker Testing in Lung Cancer

May 19th 2022

Eric Vail, MD, discusses emerging advances in biomarker testing in lung cancer.

Dr. Massarelli Discusses Frontline Immunotherapy in NSCLC

May 19th 2022

Erminia Massarelli, MD, PhD, MS, discusses advances in front-line immunotherapy in non–small cell lung cancer.

Dr. Harari on Upright Proton Radiation Therapy in Cancer Care

May 19th 2022

Paul M. Harari, MD, discusses the new upright delivery method of proton radiation therapy in cancer care.

Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma

May 19th 2022

Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

Dr. Blay on the Current Treatment Challenges in Soft Tissue Sarcomas

May 19th 2022

Jean-Yves Blay, MD, discusses current treatment challenges in soft tissue sarcomas.

Dr. Oberstein on Remaining Challenges in Metastatic CRC

May 17th 2022

Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.

Dr. Grivas on the Future of the TROPHY U-01 Regimen in Urothelial Cancer

May 17th 2022

Petros Grivas, MD, PhD, discusses the future of the phase 2 TROPHY U-01 trial regimen in metastatic urothelial cancer.

Dr. Ornstein on Unmet Needs in Refractory RCC

May 17th 2022

Moshe Ornstein, MD, MA, discusses unmet needs in metastatic renal cell carcinoma.

Dr. Oberstein on the CheckMate 9X8 Trial in Metastatic CRC

May 17th 2022

Paul E. Oberstein, MD, discusses the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Dr. Fleming on the KEYNOTE-426 Trial in Metastatic RCC

May 17th 2022

Mark T. Fleming, MD, discusses the phase 3 KEYNOTE-426 trial in advanced or metastatic renal cell carcinoma.